SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (89)2/16/2000 1:34:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1833
 
Message 12883399



To: scaram(o)uche who wrote (89)2/16/2000 10:13:00 AM
From: Dave K  Read Replies (1) | Respond to of 1833
 
>> what does everyone include in their valuation models for royalties? I have $24 million for 2006, assigning $0 to SmithKline <<

Rick, what's your breakdown ? I've been assuming Smithkline was out of the picture ? However your reference to them reminded me that I recall seeing mentioned that Cadus delivered (9 ?) targets to them (in 1998 ?). Is this where royalties are expected assuming SKB development proceeds ?

Dave



To: scaram(o)uche who wrote (89)2/16/2000 10:28:00 AM
From: Dave K  Read Replies (1) | Respond to of 1833
 
>> Look for the PTO decision by May?!? <<

Would PTO will key off appeal results (unfair question). As I understand, PTO overules any court decision. Then (sorry to mention this) Pfizer follows with their own patent challenge.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News